Manassas, Virginia--(Newsfile Corp. - July 9, 2025) - Notal Vision, a digital healthcare provider advancing remote patient monitoring in ophthalmology, announced the publication of pivotal study data ...
Please provide your email address to receive an email when new articles are posted on . Home OCT may help patients achieve extended dosing intervals through consistent fluid evaluation. Scans are ...
Please provide your email address to receive an email when new articles are posted on . One presenter said at-home OCT has the potential to improve outcomes in neovascular AMD through personalized ...
Needham initiated coverage on Ocular Therapeutix Inc (NASDAQ:OCUL), noting the company’s lead asset, Axpaxli, an investigational axitinib-based intravitreal implant for wet age-related macular ...
ALPHARETTA, Ga., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI’s unmatched durability in wet AMD with sustained disease control AXPAXLI demonstrated robust CSFT control with a median time of 39 weeks ...
(RTTNews) - EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last October, expects to report full topline results in the first ...
—With a greater number of treatments available for age-related macular degeneration (AMD), it’s more important than ever that patients’ progression of geographic atrophy (GA) secondary to AMD is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results